Millipore Sigma Vibrant Logo

05-1072 Anti-Ras Antibody, (K-, H-, N-), clone 9A11.2

View This Product on Sigma-Aldrich
05-1072
100 µg  
価格を検索中…
価格が見つかりません
Minimum Quantity needs to be mulitiple of
Maximum Quantity is
弊社照会 詳細を表示 
値引
()
 
弊社照会
現在国内在庫なし
現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      Special Offers[海外情報]

       

      お問合せください

      概要

      Replacement Information

      Special Offers[海外情報]

      主要スペック表

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RWB, IH(P)MPurifiedMonoclonal Antibody
      Description
      Catalogue Number05-1072
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-Ras Antibody, (K-, H-, N-), clone 9A11.2
      Background InformationRas, a proto-oncogene, is a small G-protein that has 3 primary isoforms (H-Ras, N-Ras, and K-Ras) that differ in there approximately 20 C-terminal amino acids. H-Ras was first discovered as a transforming product the retrovirus Harvey murine virus and K-Ras of Kirten sarcoma virus. Ras is a heavily studied target of both academic and pharmaceutical research because of its implications in various pathways and diseases as well as being mutated in a large number of human cancers. Ras is most notably the activator of the Erk/MAPK kinase pathway as activator of Raf, as well as an activator of PI3 Kinase (PI3K). In its oncogenic, mutated state, Ras is unable to hydrolyze GTP to GDP, thus staying in an active state and activating numerous pathways including the MAPK pathway through its activation of Raf, but also others as well that include PI3 Kinase and RalGDS. One path that the pharmaceutical industry has taken to control Ras and its activity is by finding what some consider its Achilles’ heel. For its activation, Ras must localize to the plasma membrane, but interestingly, it lacks a transmembrane domain. To achieve this, Ras must first undergo a post-translational modification (PTM) known as prenylation or geranylation at its C-terminal CAAX motif. For this to take place, a controlled three step process must occur. The first step in the process is the prenylation or geranylation of the C in the CAAX motif that is initiated by the covalent attachment of farnesyl groups to the cysteine that is catalyzed by the heterodimer enzymes farnesyl transferases and . After this modification, the –aaX of the motif is proteolytically removed via Rce1 (Ras Converting Enzyme 1), a membrane associated endoprotease, by a mechanism that is still not fully understood. Finally, the C-terminal prenylcysteine is now methlylated by ICMT (Isoprenylcysteine Carboxymethyl Transferase). These drugs have yet to pass clinical trials though and there is doubt that they will ever be successful in treating tumors associated with Ras activation.
      References
      Product Information
      FormatPurified
      PresentationProtein G purified mouse monoclonal in storage buffer containing 0.1M Tris-Glycine (pH 7.4), 15mM NaCl, and 0.05% NaN3.
      Quality LevelMQ100
      Applications
      ApplicationThis Anti-Ras Antibody, (K-, H-, N-), clone 9A11.2 is validated for use in WB, IH(P) for the detection of Ras.
      Key Applications
      • Western Blotting
      • Immunohistochemistry (Paraffin)
      Biological Information
      ImmunogenFull length recombinant GST-tagged human H-Ras.
      Clone9A11.2
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostMouse
      SpecificityRecognizes K-, H-, and N-Ras (all 3 isofroms).
      IsotypeIgG1κ
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryMembers of the RAS superfamily of GTP-binding proteins, which includes MRAS, are membrane-anchored, intracellular signal transducers responsible for a variety of normal cellular functions. They are oncogenically activated in a significant fraction of tumors.[supplied by OMIM]
      Gene Symbol
      • K-Ras
      • Ki-Ras
      • K-Ras2
      • Kras-2
      • p21B
      • KRAS
      • RASK2
      • HRAS
      • HA_RAS
      • N-RAS
      • H-RAS
      • NRAS
      • NRAS1
      • ALPS4
      Purification MethodProtein G Purified
      UniProt Number
      UniProt SummaryFUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
      Enzyme regulation:Alternate between an inactive form bound to GDP and an active form bound to GTP. Activated by a guanine nucleotide-exchange factor (GEF) and inactivated by a GTPase-activating protein (GAP).
      SIZE: 189 amino acids; 21,656 Da
      SUBUNIT: Interacts with PHLPP (By similarity).
      SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor; Cytoplasmic side.
      Involvement in disease:
      Defects in KRAS are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.

      Defects in KRAS are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor.

      Defects in KRAS are the cause of Noonan syndrome 3 (NS3) [MIM:609942]. Noonan syndrome (NS) [MIM:163950] is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. It is a genetically heterogeneous and relatively common syndrome, with an estimated incidence of 1 in 1000-2500 live births. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS3 inheritance is autosomal dominant.

      Defects in KRAS are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.

      KRAS mutations are involved in cancer development.
      Molecular Weight21 kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated by immunoblot on RIPA lysate from human A431 carcinoma cells, mouse 3T3, mouse brain, orrat brain.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 4°C from date of receipt.
      Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      05-1072 04053252585272

      Documentation

      Anti-Ras Antibody, (K-, H-, N-), clone 9A11.2 (M)SDS

      タイトル

      英語版製品安全データシート((M)SDS) 

      Anti-Ras Antibody, (K-, H-, N-), clone 9A11.2 試験成績書(CoA)

      タイトルロット番号
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 2444150 2444150
      Anti-Ras (K-,H-,N-), clone 9A11.2 - NG1752500 NG1752500
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 2198978 2198978
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 2325713 2325713
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 2363937 2363937
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 2517760 2517760
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 3249934 3249934
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 3385816 3385816
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 3499850 3499850
      Anti-Ras (K-,H-,N-), clone 9A11.2 - 3695879 3695879

      参考資料

      参考資料の概要アプリケーションPub Med ID
      Innate inflammation induced by the 8-oxoguanine DNA glycosylase-1-KRAS-NF-κB pathway.
      Aguilera-Aguirre, L; Bacsi, A; Radak, Z; Hazra, TK; Mitra, S; Sur, S; Brasier, AR; Ba, X; Boldogh, I
      Journal of immunology (Baltimore, Md. : 1950)  193  4643-53  2014

      概要を表示する
      25267977 25267977
      Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele.
      Wang, Z; Feng, Y; Bardeesy, N; Bardessy, N; Wong, KK; Liu, XY; Ji, H
      PloS one  7  e37308  2012

      概要を表示する
      Western Blotting22606359 22606359

      カタログ

      タイトル
      Advancing cancer research: From hallmarks & biomarkers to tumor microenvironment progression

      関連製品&アプリケーション

      Related Products

      カタログ番号 説明  
      05-516 Anti-Ras Antibody, clone RAS10 価格&在庫状況を表示
      16-321 Anti-Ras Magnetic Bead Conjugate Antibody 価格&在庫状況を表示
      MABS195 Anti-Pan-Ras Antibody, clone RAS 10 価格&在庫状況を表示

      製品ファミリー

      カテゴリー

      Life Science Research > Antibodies and Assays > Primary Antibodies